NXgenPort addresses an unmet need in cancer care by remotely managing patients between chemotherapy treatments with a Software as a Medical Device (SaMD) and an implanted Smart Port with intravascular cytometry sensors. By using machine learning to measure blood cell counts, vitals, and heart function in vivo, NXgenPort will alert doctors to early signs of infection, determine readiness for next treatment, and improve health equity and access.